Clinical Trials Logo

Clinical Trial Summary

This phase I/II trial identifies the best dose and side effects of selinexor, and how well it works when given in combination with pomalidomide and dexamethasone with or without carfilzomib in treating patients with multiple myeloma that has come back (relapsed) and does not respond to treatment with proteasome inhibitors and immunomodulatory drugs (refractory). Selinexor is an oral agent that blocks a protein called Exportin 1 (XPO1 or CRM1) that is abundant in a wide variety of cancers, including multiple myeloma. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Pomalidomide may stop the growth of blood vessels, stimulate the immune system, and kill cancer cells. Anti-inflammatory drugs, such as dexamethasone may lower the body's immune response and are used with other drugs in the treatment of some types of cancer. The addition of selinexor may allow better control of relapsed refractory multiple myeloma than is possible with pomalidomide and dexamethasone with or without carfilzomib.


Clinical Trial Description

PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose (MTD) of selinexor in combination with carfilzomib, pomalidomide and dexamethasone (SKPd) in patients with relapsed refractory multiple myeloma (RRMM). (Arm A) II. To determine the efficacy of fixed-dose selinexor in combination with low-dose pomalidomide and dexamethasone (SPd) in patients with RRMM as measured by the overall response rate (ORR) per the International Myeloma Working Group (IMWG) criteria. (Arm B) SECONDARY OBJECTIVES: I. To evaluate the preliminary efficacy of SKPd in relapsed/refractory multiple myeloma, as measured by the overall response rate (ORR) per International Myeloma Working Group (IMWG) criteria and the duration of response (DOR). (Arm A) II. To evaluate clinical benefit rate (CBR), duration of response, progression-free survival, overall survival, and the safety profile of SPd. (Arm B) EXPLORATORY OBJECTIVES: I. To estimate clinical activity in different risk groups by cytogenetics. II. To assess minimal residual disease by flow cytometry in patients achieving complete response (CR) and compare the outcomes of patients who are serum mass-fix (mass spectrometry-based methodology available at Mayo Clinic) negative only versus those who have no evidence of disease by mass fix and flow-cytometry-based minimal residual disease (MRD). III. To assess overall health-related quality of life, as measured by the global health domain of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire and Quality of Life Questionnaire-Multiple Myeloma 20 (QLQ-MY20). IV. To evaluate patient reported outcomes using the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (Patient Reported Outcomes Version of Common Terminology Criteria for Adverse Events [PRO-CTCAE]). V. To stratify patients in arm A based on quadruple/penta-refractory status and to assess the impact of this stratification on patient outcomes. VI. To stratify patients in arm B based on their dual-refractory status and to assess the impact of this stratification on patient outcomes. OUTLINE: Patients with >= 3 prior lines of therapy are assigned to Arm A, while patients with 1-2 prior lines of therapy are assigned to Arm B. Arm A is a phase I dose-escalation study of selinexor and carfilzomib, with fixed-dose dexamethasone and pomalidomide followed by a dose-expansion study. Arm B is a phase II fixed-dose study of selinexor, dexamethasone, and pomalidomide. ARM A: Patients receive selinexor orally (PO) and dexamethasone PO on days 1, 8 15, and 22, carfilzomib intravenously (IV) on days 1, 8, and 15, and pomalidomide PO on days 1-21. Treatment repeats every 28 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo x-ray imaging during screening. Patients also undergo positron emission tomography/computed tomography (PET/CT) or CT and bone marrow biopsy and aspiration during screening and on the trial. Patients may optionally undergo blood sample collection during screening and on the trial. ARM B: Patients receive selinexor PO and dexamethasone PO on days 1, 8, 15, and 22, and pomalidomide PO on days 1-21. Treatment repeats every 28 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo x-ray imaging during screening. Patients also undergo PET/CT or CT and bone marrow biopsy and aspiration during screening and on the trial. Patients may optionally undergo blood sample collection during screening and on the trial. After completion of study treatment, patients are followed up at 30 days, then every 3 months until progressive disease (PD) or subsequent treatment, then every 6 months until 3 years from registration. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04764942
Study type Interventional
Source Mayo Clinic
Contact Clinical Trials Referral Office
Phone 855-776-0015
Email mayocliniccancerstudies@mayo.edu
Status Recruiting
Phase Phase 1/Phase 2
Start date May 6, 2021
Completion date March 4, 2026

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04083534 - First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM) Phase 1/Phase 2
Completed NCT01775553 - Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib Phase 2
Terminated NCT02020941 - Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy Phase 2
Completed NCT01212952 - Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Phase 1/Phase 2
Terminated NCT01078441 - Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant Phase 2
Completed NCT01233921 - Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer N/A
Completed NCT00514137 - Sunitinib in Treating Patients With Relapsed Multiple Myeloma Phase 2
Completed NCT00306813 - Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple Myeloma Phase 1/Phase 2
Completed NCT00078858 - Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant Phase 1/Phase 2
Completed NCT00047203 - Flavopiridol in Treating Patients With Relapsed or Refractory Multiple Myeloma Phase 2
Active, not recruiting NCT03731832 - Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple Myeloma Phase 2
Completed NCT00003196 - Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma N/A
Recruiting NCT03601624 - Pomalidomide/Cyclophosphamide/Dexamethasone in Relapse Refractory Myeloma: Safety Profile in Mexicans Phase 2
Terminated NCT01954784 - Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma Phase 1
Recruiting NCT05020444 - TriPRIL CAR T Cells in Multiple Myeloma Phase 1
Completed NCT01588015 - Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant Phase 1
Recruiting NCT04302324 - A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab Phase 2
Recruiting NCT06119685 - IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers Phase 1/Phase 2
Completed NCT00118170 - Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function Phase 1
Completed NCT00054353 - Reduced-Intensity Conditioning Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma Phase 1/Phase 2